Last week (from January 24 to January 28), the pre reduction scale of A-share companies decreased. According to incomplete statistics of interface news, a total of 45 A-share companies disclosed shareholder reduction plans.
In terms of reduction, Pharmaron Beijing Co.Ltd(300759) (300759. SZ) was reduced by two major shareholders, not exceeding 6% of the total share capital; Apt Medical Inc(688617) (688617. SH) was underweight when its share price fell continuously.
In terms of shareholding increase, after China Mobile (600941. SH) was increased by the actual controller last week, another giant China Telecom Corporation Limited(601728) (601728. SH) also threw out a large shareholding increase plan.
share price halved Pharmaron Beijing Co.Ltd(300759) was reduced
On December 26, Apt Medical Inc(688617) announced that the shareholders of the company, Qiming Chuangzhi and its concerted actors, Qihua phase III, Qiming Rongke and Qiming Rongying, planned to reduce their holdings of no more than 1441400 shares, that is, no more than 2.162% of the total share capital of the company. Qiming Weichuang, the shareholder, and qm33, the person acting in concert, intend to reduce their total holdings of no more than 1558600 shares, that is, no more than 2.3378% of the total share capital of the company. Han Yonggui, deputy general manager of the company, plans to reduce his holdings of no more than 30900 shares, that is, no more than 0.0463% of the total share capital of the company. The reduction scale of the above shareholders totaled 3030900 shares. According to the reduction quantity and the closing price on the day of announcement, the above shareholders reduced their holdings and cashed out about 657 million yuan.
Apt Medical Inc(688617) at present, the main business is dominated by complete coronary artery access and electrophysiological medical devices, with peripheral vascular and nerve interventional medical devices as the key development direction. On January 28, the company disclosed the performance forecast, which shows that the net profit attributable to the owners of the parent company is expected to be 192 million yuan to 209 million yuan in 2021, an increase of 73.32% to 88.67% year-on-year compared with the same period of the previous year (statutory disclosure data). In July 2021, the company’s share price rose from a record high of 468.77 yuan / share, and has fallen by nearly 60%.
On January 26, Visual China Group Co.Ltd(000681) (000681. SZ) announced that the controlling shareholder and actual controller Liao daoxun, Wu Yurui, Liang Jun and Chai Jijun planned to reduce their holdings of no more than 28023100 shares of the company (accounting for 4% of the total share capital of the company). According to the number of holdings reduced and the closing price on the day of the announcement, the above shareholders reduced their holdings and cashed out about 559 million yuan.
Before the disclosure of the reduction plan, Visual China Group Co.Ltd(000681) share price had just experienced a sharp rise. With the concept of “meta vision” and blockchain, the share price of Visual China Group Co.Ltd(000681) with mediocre performance has risen all the way since the second half of last year, climbing from the low of 10.63 yuan / share to the high of 27.6 yuan / share, with an increase of about 150%. As of the closing on January 28, the company reported 17.27 yuan / share, down nearly 40% from the high point.
On January 25, Pharmaron Beijing Co.Ltd(300759) announced that shareholders Xinzhong Kangcheng and Xinzhong Longcheng planned to reduce their holdings of no more than 47650500 shares of the company (accounting for 6% of the total share capital of the company). According to the estimation of the reduction quantity and the closing price on the day of the announcement, the total reduction and cash out of the above shareholders exceeded 6.2 billion yuan.
The main business types of Pharmaron Beijing Co.Ltd(300759) can be divided into four service modules: laboratory service, CMC (small molecule cdmo) service, clinical research service, macromolecule and cell and gene therapy service. Pharmaron Beijing Co.Ltd(300759) is the fifth largest heavy position stock of China Europe medical health, the representative work of 100 billion top flow fund manager Ge Lan. The company is also the public fund with the largest position of Pharmaron Beijing Co.Ltd(300759) . According to the performance forecast of Pharmaron Beijing Co.Ltd(300759) 2021 annual report, the company expects to realize an operating revenue of 7.341-7.495 billion yuan in 2021, with a year-on-year increase of 43% – 46%; The net profit attributable to the parent company was RMB 1.583-1.700 billion, with a year-on-year increase of 35% – 45%. With the correction of pharmaceutical stocks, Pharmaron Beijing Co.Ltd(300759) in the past six months, the share price per share fell by more than 120 yuan, with a cumulative decline of nearly 50%.
to stabilize the stock price China Telecom Corporation Limited(601728) sell and increase the shareholding plan
On January 27, China Telecom Corporation Limited(601728) announced that the controlling shareholder China Telecom Corporation Limited(601728) group plans to increase its holdings by no less than 500 million yuan within 12 months from January 28, 2022. There is no price range for this increase, and the source of the increase is its own funds. The 4 billion yuan share increase plan disclosed by the company on September 22, 2021 is still within the implementation period, which is implemented separately from the stable share price increase plan.
Since its listing in August 2021, China Telecom Corporation Limited(601728) share price has been in a slump. After the break, it is broken. As of the closing on January 28, the company’s share price was reported at 4.16 yuan / share.
On January 25, Jianxi Lianchuang Opto-Electronic Science&Technology Co.Ltd(600363) (600363. SH) announced that the controlling shareholder Electronics Group plans to hold an additional 20-100 million yuan of shares. The company’s main business is the R & D, production and sales of intelligent control series products, backlight series products, photoelectric communication and intelligent equipment cables and metal materials products, semiconductor laser series and aviation Sichuan Tianwei Electronic Co.Ltd(688511) components products. In August 2021, the company’s share price went out of a record high of 40.1 yuan / share, and now it has fallen by nearly 40%. Since the end of last month, several executives of the company have thrown out the reduction plan.
On January 24, Jiangsu Zhongsheng Gaoke Environmental Co.Ltd(002778) (002778. SZ) announced that Xu Chundong, the director of the company, plans to increase his holding of the company’s shares by means of centralized bidding trading within four months from the date of the plan announcement, and the amount of the proposed increase shall not be less than 30 million yuan. Jiangsu Zhongsheng Gaoke Environmental Co.Ltd(002778) it is mainly engaged in the R & D, production and sales of various lubricating oil products. It is one of the leading manufacturers of industrial lubricating oil products in China. Recently, Jiangsu Zhongsheng Gaoke Environmental Co.Ltd(002778) company chairman and director Zhang Jun resigned.
